News | March 12, 2015

Interventional Radiology Offers New Treatment for Enlarged Prostates

Research demonstrates prostate artery embolization effectiveness for benign prostatic hyperplasia, with low side effects

BPH, prostate, interventional radiology, PAE, embolization, SIR

March 12, 2015 — Men with benign prostatic hyperplasia (BPH), have a new, breakthrough treatment option that is less invasive and has fewer complications than other minimally invasive treatments, according to research presented at the Society of Interventional Radiology's (SIR's) Annual Scientific Meeting.

BPH is a condition in which the prostate is enlarged but not cancerous. Using an interventional radiology treatment known as prostate artery embolization (PAE), clinicians were able to improve patient symptoms, regardless of the size of BPH before the treatment, researchers found in a retrospective study.

"As healthcare moves toward more patient-centered care, it's critical that interventional radiologists, in collaboration with urologists, are able to provide BPH patients with a relatively painless, outpatient procedure," said Sandeep Bagla, M.D., the study's lead researcher and an interventional radiologist at Inova Alexandria Hospital in Virginia. "This innovative treatment offers less risk, less pain and less recovery time than traditional surgery, and we are hopeful that further research will confirm it to be an effective therapy for BPH," he added.

In prostate artery embolization, a catheter is inserted into the femoral artery and guided to the prostate artery on both sides of the enlarged gland. Once positioned next to the prostate, microscopic spheres are delivered to block blood flow, causing the prostate to shrink. PAE is technically challenging, said Bagla. Interventional radiologists, given their knowledge of arterial anatomy, experience with microcatheter techniques and expertise in other embolization procedures, are the specialists best suited for the performance of PAE. He also noted that SIR supports the performance of high-quality clinical research to expand the numbers of patients studied, to extend the duration of follow-up and to compare the PAE procedure against existing surgical therapies.

Bagla and his team examined the cases of 78 patients who underwent prostate artery embolization for BPH as part of the clinicians' routine practice. Patients were categorized into three different analysis groups based on the size of the enlarged prostate: less than 50 cubic centimeters, between 50-80 cubic centimeters and greater than 80 cubic centimeters. The researchers evaluated the effectiveness of PAE in these patients at one, three and six months post-treatment.

Ninety-six percent of cases (75 of 78) were considered technically successful, with both blood vessels leading to the enlarged prostate blocked by PAE treatment. The researchers found symptom improvement and that quality of life, as measured by the American Urological Association Symptom Index, significantly improved in all three patient groups. When comparing each group, there was no difference in outcome as well. Using the International Index of Erectile Function, patients also did not report a change in their sexual function. Bagla attributes this low rate of side effects to the fact that PAE is conducted via the femoral artery versus other treatments, which enter through the urethra or penis.

"Many men have benign prostatic hyperplasia that cannot be treated by traditional methods, such as when the BPH is smaller than 50 cubic centimeters or larger than 80 cubic centimeters," said Bagla. "Prostate artery embolization offers these patients an effective treatment that results in reduced risk of bleeding, urinary incontinence or impotence, compared to other BPH therapies, offering patients a better quality of life," he added.

While the data from this research demonstrate continued symptomatic improvement six months after treatment, more research is needed to show efficacy at one year and beyond, added Bagla. He also believes that additional research — possibly randomized, prospective studies — should be done to compare the safety and efficacy of PAE with other commonly performed BPH treatments.

BPH affects more than 50 percent of men ages 60 and older in the United States, and more than 80 percent of men 80 and over, according to Bagla.

For more information: www.sirweb.org

Related Content

Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
Exact Imaging Partners to Improve Prostate Cancer Detection With Artificial Intelligence
News | Prostate Cancer | September 19, 2018
Exact Imaging, makers of the ExactVu micro-ultrasound platform, has partnered with U.K.-based Cambridge Consultants to...
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...

Image courtesy of IBA

Feature | Radiation Oncology | September 07, 2018 | By Jeff Zagoudis
According to the latest statistics from the American Cancer Society (ACS), almost 165,000 new cases of prostate cancer...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Check-Cap Announces Interim Results of European Study of C-Scan System Version 3
News | Colonoscopy Systems | September 04, 2018
Check-Cap Ltd. announced the interim results for its post-CE approval study of the C-Scan system Version 3, an...
Brain Iron Levels May Predict Multiple Sclerosis Disabilities
News | Neuro Imaging | August 31, 2018
A new, highly accurate magnetic resonance imaging (MRI) technique can monitor iron levels in the brains of multiple...
Study Finds Multiple Sclerosis Drug Slows Brain Shrinkage

An NIH-funded clinical trial suggested that the anti-inflammatory drug ibudilast may slow brain shrinkage caused by progressive MS. Image courtesy of Robert J. Fox, M.D., Cleveland Clinic.

News | Neuro Imaging | August 30, 2018
August 30, 2018 — Results from a clinical...
Rapid Cardiac MRI Technique May Cut Costs, Boost Care in Developing World
News | Magnetic Resonance Imaging (MRI) | August 29, 2018
A newly developed rapid imaging protocol quickly and cheaply diagnosed heart ailments in patients in Peru, according to...